Back to Search
Start Over
Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma
- Source :
- HeadneckREFERENCES. 43(3)
- Publication Year :
- 2020
-
Abstract
- Data relating to the efficacy of immune checkpoint inhibitors (ICI) for salivary gland carcinomas (SGC) is gradually evolving with responses varying among different histotypes. To address these disparities, this retrospective analysis examined the prevalence of recognized biomarkers of response to ICI; namely programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), combined positive score (CPS), epidermal growth factor receptor (EGFR), and microsatellite instability (MSI) in patients with SGC with an aim to determine any prognostic or survival benefits and stratify the use of ICI in this disease. Of 52 patients with primary SGC eligible for this study, the most common histological types were adenoid cystic carcinoma (n = 17, 33%), salivary duct carcinoma (n = 14, 27%), mucoepidermoid carcinoma (n = 11, 21%), and acinic cell carcinoma (n = 6, 11%). Immunohistochemistry (IHC) was performed using the Ventana Discovery Ultra auto-staining platform for EGFR, PD-1, PD-L1, and mismatch repair (MMR) proteins. CPS ≥1 defined PD-L1 positive cases and log-rank testing was performed to examine the relationship between PD-L1 expression status and disease-free survival (DFS) and overall survival (OS). CPS positivity was seen in 9 (17.3%) patients, none of which were adenoid cystic carcinoma. All 52 (100%) cases expressed retained MMR proteins inferring microsatellite stability (MSS) and EGFR expression was identified in 45 of 52 (86.5%) patients. CPS positivity (score ≥1) was significantly associated with advanced pathological T status (P = .021), advanced pathological N status (P = .006), high histological tumor grade (P = .045), and positive histological margin (P = .023). Patients with PD-L1 positivity in tumor cells did not have an inferior 3-year OS (P = .93). The data from this retrospective study highlighting the uniform microsatellite stability alongside the low prevalence of CPS positivity suggests that only a minority of SGC patients may benefit from ICI therapy alone. The high rates of EGFR expression in SGC may be a target to augment immune checkpoint therapy response.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Adenoid cystic carcinoma
B7-H1 Antigen
Salivary Glands
Salivary duct carcinoma
Acinic cell carcinoma
03 medical and health sciences
0302 clinical medicine
Mucoepidermoid carcinoma
Internal medicine
PD-L1
medicine
Biomarkers, Tumor
Humans
Retrospective Studies
biology
business.industry
Carcinoma
Microsatellite instability
medicine.disease
Immune checkpoint
ErbB Receptors
030104 developmental biology
Otorhinolaryngology
030220 oncology & carcinogenesis
biology.protein
Immunohistochemistry
business
Subjects
Details
- ISSN :
- 10970347
- Volume :
- 43
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- HeadneckREFERENCES
- Accession number :
- edsair.doi.dedup.....11b8d12f388778ff35df7c203a32d973